bioMérieux will assess AST/AES results and validate against evolving global antimicrobial susceptibility data collected through the JMI-led SENTRY program.
Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens.
Vicki Barbur of Battelle discusses real-time microbiology, critical factors determining the rapid method of choice, and accessibility to new technologies